Neuro-Oncology Reviews
Volume
24 Number 17
15 September 2022
Home > Publications > Neuro-Oncology Reviews > Volume 24, Year 2022 > Number 17, 15 September
Khalil
M, Shah Z, Saeed Baqai MW, Shamim MS.
Intraoperative
Seizures During Awake Craniotomy for Brain Tumours.
J
Pak Med Assoc. 2022 Sep;72(9):1878-1879→.
doi: 10.47391/JPMA.22-95? PMID: 36281000→.
Review. ˍ
Jain
H, Dhawan P, Rao S, Lalwani N, Shand H.
The
impediments of cancer stem cells and an exploration into the
nanomedical solutions for glioblastoma.
Anticancer
Agents Med Chem. 2022 Sep 1→.
doi: 10.2174/1871520622666220901101204→.
PMID: 36056850→.
Review˰ ˍ
Karami
Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh SD,
Pourghasem Z, Abbasi Oshagh P, Azargoonjahromi A, Almasi F,
Manzoor HZ, Khalesi B, Pourzardosht N, Khalili S, Payandeh
Z.
Recent
Advances in Glioma Cancer Treatment: Conventional and Epigenetic
Realms.
Vaccines
(Basel). 2022 Sep 2;10(9):1448→.
doi: 10.3390/vaccines10091448→.
PMID: 36146527→.
Review. ˍ
Prajapati
HP, Singh DK.
Recurrent
glioblastoma in elderly: Options and decision for the
treatment.
Surg
Neurol Int. 2022 Sep 2;13:397→.
doi: 10.25259/SNI_552_2022→.
PMID: 36128156→.
Review. ˍ
van
der Meulen M, Ramos RC, Mason WP, Von Deimling A, Maas
SLN.
Opinion
& Special Article: Glioma Classification: How to Interpret
Molecular Markers in a Diffuse Glioma Pathology Report.
Neurology.
2022 Sep 2:10.1212/WNL.0000000000201262→.
doi: 10.1212/WNL.0000000000201262→.
PMID: 36240081→.
Review. ˍ
*
Li
S, Dong J, Wang X, Meng X, Jiang C, Cai J.
Dexamethasone
and compliance affect TTFields efficacy to glioblastoma patients:
a systematic review and meta-analysis.
Chin
Neurosurg J. 2022 Sep 3;8(1):24→.
doi: 10.1186/s41016-022-00294-0→.
PMID: 36056409→.
Review, Meta-analysis. ˍ
Yang
T, Liu D, Fang S, Ma W, Wang Y.
Cytomegalovirus
and Glioblastoma: A Review of the Biological Associations and
Therapeutic Strategies.
J
Clin Med. 2022 Sep 4;11(17):5221→.
doi: 10.3390/jcm11175221→.
PMID: 36079151→.
Review. ˍ
Davoodvandi
A, Nikfar B, Reiter RJ, Asemi Z.
Melatonin
and cancer suppression: insights into its effects on DNA
methylation.
Cell
Mol Biol Lett. 2022 Sep 5;27(1):73→.
doi: 10.1186/s11658-022-00375-z→.
PMID: 36064311→.
Review. ˍ
Low
SK, Anjum Z, Mahmoud A, Joshi U, Kouides P.
Isocitrate
dehydrogenase mutation and risk of venous thromboembolism in
glioma: A systematic review and meta-analysis.
Thromb
Res. 2022 Sep 5;219:14-21→.
doi: 10.1016/j.thromres.2022.08.029→.
PMID: 36088710→.
Review, Meta-analysis˰ ˍ
Mirzaei
R, Yong VW.
Microglia-T
cell conversations in brain cancer progression.
Trends
Mol Med. 2022 Sep 5:S1471-4914(22)00211-8→.
doi: 10.1016/j.molmed.2022.08.006→.
PMID: 36075812→.
Review˰ ˍ
*
Cheng
K, Zhang H, Guo Q, Zhai P, Zhou Y, Yang W, Wang Y, Lu Y, Shen Z,
Wu H.
Emerging
trends and research foci of oncolytic virotherapy for central
nervous system tumors: A bibliometric study.
Front
Immunol. 2022 Sep 6;13:975695→.
doi: 10.3389/fimmu.2022.975695→.
PMID: 36148235→.
Bibliometric analysis. ˍ
Hersh
AM, Jallo GI, Shimony N.
Surgical
approaches to intramedullary spinal cord astrocytomas in the age
of genomics.
Front
Oncol. 2022 Sep 6;12:982089→.
doi: 10.3389/fonc.2022.982089→.
PMID: 36147920→.
Review. ˍ
Śledzińska
P, Bebyn M, Furtak J, Koper A, Koper K.
Current
and promising treatment strategies in glioma.
Rev
Neurosci. 2022 Sep 6→.
doi: 10.1515/revneuro-2022-0060→.
PMID: 36062548→.
Review˰ ˍ
Wang
Z, Chen G.
Insights
about circadian clock in glioma: From molecular pathways to
therapeutic drugs.
CNS
Neurosci Ther. 2022 Sep 6→.
doi: 10.1111/cns.13966→.
PMID: 36066207→.
Review. ˍ
Gales
L, Forsea L, Mitrea D, Stefanica I, Stanculescu I, Mitrica R,
Georgescu M, Trifanescu O, Anghel R, Serbanescu L.
Antidiabetics,
Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in
Cancer Therapy.
Medicina
(Kaunas). 2022 Sep 7;58(9):1239→.
doi: 10.3390/medicina58091239→.
PMID: 36143915→.
Review. ˍ
Sethi
B, Kumar V, Mahato K, Coulter DW, Mahato RI.
Recent
advances in drug delivery and targeting to the brain.
J
Control Release. 2022 Sep 7;350:668-687→.
doi: 10.1016/j.jconrel.2022.08.051→.
PMID: 36057395→.
Review˰ ˍ
Amadasu
E, Panther E, Lucke-Wold B.
Characterization
and Treatment of Spinal Tumors.
Intensive
Care Res. 2022 Sep 8;2(3-4):76-95→.
doi: 10.1007/s44231-022-00014-3→.
PMID: 36741203→.
Review. ˍ
Pappo
AS, Karol SE, Bertrand KC.
Top
advances of the year: Pediatric oncology.
Cancer.
2022 Sep 8→.
doi: 10.1002/cncr.34425→.
PMID: 36074012→.
Review. ˍ
Khayamzadeh
M, Niazi V, Hussen BM, Taheri M, Ghafouri-Fard S, Samadian
M.
Emerging
role of extracellular vesicles in the pathogenesis of
glioblastoma.
Metab
Brain Dis. 2022 Sep 9→.
doi: 10.1007/s11011-022-01074-6→.
PMID: 36083425→.
Review˰ ˍ
Qi
Z, Long X, Liu J, Cheng P.
Glioblastoma
microenvironment and its reprogramming by oncolytic
virotherapy.
Front
Cell Neurosci. 2022 Sep 9;16:819363→.
doi: 10.3389/fncel.2022.819363→.
PMID: 36159398→.
Review. ˍ
Lukas
RV, Chmura SJ, Parney IF, Mammoser A, Smith SM, Li
J.
Neuro-oncology
at the American Society for Clinical Oncology 2022 Annual
Meeting.
Neurooncol
Pract. 2022 Sep 10;9(6):552-55→.
doi: 10.1093/nop/npac071→.
PMID: 36388417→.
Meeting report˰ ˍ
*
Aquilanti
E, Wen PY.
Current
therapeutic options for glioblastoma and future
perspectives.
Expert
Opin Pharmacother. 2022 Sep 13→.
doi: 10.1080/14656566.2022.2125302→.
PMID: 36100970→.
Review˰ ˍ
Naser
R, Dilabazian H, Bahr H, Barakat A, El-Sibai M.
A
guide through conventional and modern cancer treatment modalities:
A specific focus on glioblastoma cancer therapy (Review).
Oncol
Rep. 2022 Sep 13;48(5):190→.
doi: 10.3892/or.2022.8405→.
PMID: 36102321→.
Review˰ ˍ
Pasqualetti
F, Rizzo M, Franceschi S, Lessi F, Paiar F, Buffa FM.
New
perspectives in liquid biopsy for glioma patients.
Curr
Opin Oncol. 2022 Sep 13→.
doi: 10.1097/CCO.0000000000000902→.
PMID: 36093876→.
Review˰ ˍ
Sales
AHA, Beck J, Schnell O, Fung C, Meyer B, Gempt J.
Surgical
Treatment of Glioblastoma: State-of-the-Art and Future Trends.
J
Clin Med. 2022 Sep 13;11(18):5354→.
doi: 10.3390/jcm11185354→.
PMID: 36143001→.
Review. ˍ
Tran
S, Bielle F.
WHO
2021 and beyond: new types, molecular markers and tools for brain
tumor classification.
Curr
Opin Oncol. 2022 Sep 13→.
doi: 10.1097/CCO.0000000000000903→.
PMID: 36093875→.
Review˰ ˍ
Franson
A, McClellan BL, Varela ML, Comba A, Syed MF, Banerjee K, Zhu Z,
Gonzalez N, Candolfi M, Lowenstein P, Castro MG.
Development
of immunotherapy for high-grade gliomas: Overcoming the
immunosuppressive tumor microenvironment.
Front
Med (Lausanne). 2022 Sep 14;9:966458→.
doi: 10.3389/fmed.2022.966458→.
PMID: 36186781→.
Review. ˍ
Karam
A, Mjaess G, Martinez Chanza N, Aoun F, Bou Kheir G, Younes H,
Kazzi H, Albisinni S, Roumeguère T.
CAR-T
cell therapy for solid tumors: are we still that far? A systematic
review of literature.
Cancer
Invest. 2022 Sep 14:1-35→.
doi: 10.1080/07357907.2022.2125004→.
PMID: 36102932→.
Review˰ ˍ
Torres
ID, Loureiro JA, Coelho MAN, Carmo Pereira M, Ramalho MJ.
Drug
delivery in glioblastoma therapy: a review on nanoparticles
targeting MGMT-mediated resistance.
Expert
Opin Drug Deliv. 2022 Sep 14→.
doi: 10.1080/17425247.2022.2124967→.
PMID: 36103209→.
Review˰ ˍ
*
Du
X, Chen C, Yang L, Cui Y, Tan B.
Bibliometric
and visualized analysis of the application of nanotechnology in
glioma.
Front
Pharmacol. 2022 Sep 15;13:995512→.
doi: 10.3389/fphar.2022.995512→.
PMID: 36188579→.
Bibliometric analysis. ˍ
Ghosh
M, Lenkiewicz AM, Kaminska B.
The
Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy
of Glioblastoma.
Biomedicines.
2022 Sep 15;10(9):2292→.
doi: 10.3390/biomedicines10092292→.
PMID: 36140392→.
Review. ˍ
Mitusova
K, Peltek OO, Karpov TE, Muslimov AR, Zyuzin MV, Timin
AS.
Overcoming
the blood-brain barrier for the therapy of malignant brain tumor:
current status and prospects of drug delivery approaches.
J
Nanobiotechnology. 2022 Sep 15;20(1):412→.
doi: 10.1186/s12951-022-01610-7→.
PMID: 36109754→.
Review. ˍ
Zhang
G, Fang Y, Li X, Zhang Z.
Ferroptosis:
A novel therapeutic strategy and mechanism of action in
glioma.
Front
Oncol. 2022 Sep 15;12:947530→.
doi: 10.3389/fonc.2022.947530→.
PMID: 36185243→.
Review. ˍ